Cholesterol absorption inhibitor ezetimibe: Risk– benefits and role in treating dyslipidemias

Shizuya Yamashita, Daisaku Masuda, Akifumi Matsuyama

研究成果: Chapter

抄録

Ezetimibe, a novel lipid-lowering compound, selectively inhibits intestinal cholesterol absorption by binding to Niemann-Pick C1-Like 1 (NPC1L1). Ezetimibe reduces the hepatic influx of cholesterol via chylomicron remnants, enhances the hepatic expression of low-density lipoproteins (LDL) receptor, and thus reducing LDL-cholesterol (LDL-C) levels. Ezetimibe also attenuates the development of atherosclerosis in various animal models. The administration of ezetimibe decreases the fasting levels of LDL-C in patients with primary hypercholesterolemia as well as plant sterols in patients with sitosterolemia. A significantly greater reduction in LDL-C levels is achieved in patients treated with ezetimibe plus statin combination compared with statin monotherapy. Ezetimibe was reported to decrease fasting triglycerides (TG) levels as well as postprandial TG-rich lipoprotein and remnants significantly in patients with combined hyperlipidemia and those with hypertriglyceridemia (TG ≥ 150 mg/dl); however, its underlying mechanism of action on TG-rich lipoprotein metabolism has not yet been elucidated. Ezetimibe administration can attenuate postprandial hyperlipidemia by reducing the production of chylomicrons (CMs) from the small intestines and decreasing the absorption of free fatty acids (FFA). More recently, ezetimibe has been reported to attenuate nonalcoholic fatty liver disease (NAFLD) or nonalcoholic steatohepatitis (NASH) in animal models and humans. Since the influx of chylomicron remnants and FFA into the liver is decreased by ezetimibe, it is plausible that it may attenuate hepatic lipid deposition. The antiatherosclerotic effects of ezetimibe have been demonstrated in a variety of animal models and more recently in some clinical trials. In the recent Study of Heart and Renal Protection (SHARP) Trial, the combination of simvastatin and ezetimibe was shown to be effective for major atherosclerotic events in patients with chronic kidney disease. Taken together, ezetimibe may possess additional pleiotropic roles in addition to lipid-lowering effects.

本文言語English
ホスト出版物のタイトルDyslipidemias
ホスト出版物のサブタイトルPathophysiology, Evaluation and Management
出版社Humana Press Inc.
ページ465-481
ページ数17
ISBN(電子版)9781607614241
ISBN(印刷版)9781607614234
DOI
出版ステータスPublished - 01-01-2015
外部発表はい

All Science Journal Classification (ASJC) codes

  • Medicine(all)

フィンガープリント 「Cholesterol absorption inhibitor ezetimibe: Risk– benefits and role in treating dyslipidemias」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル